Gene Therapy Patents

Gene therapy patents cover AAV capsid serotype and tissue tropism innovations; recombinant AAV vector manufacturing and purification innovations; in vivo systemic and subretinal delivery innovations; ex vivo lentiviral and transposon-mediated gene correction innovations; and synthetic promoter and transgene expression innovations — with IP held by academic medical centers, biotech companies, and pharmaceutical manufacturers: MAJOR GENE THERAPY PATENT HOLDERS: SPARK THERAPEUTICS / ROCHE: 500+; specific AAV innovations (specific specific voretigene neparvovec Luxturna: specific specific AAV2 capsid from specific specific RPE65 transgene cDNA 2.7 kb from specific specific CMV enhancer/CBA promoter from specific specific 1.5×10^11 vector genomes vg per eye from specific specific subretinal injection from specific specific FDA approval December 2017 from specific specific first in vivo gene therapy USA from specific specific RPE retinal pigment epithelium tropism from specific specific Spark100 capsid variant AAV2 from specific specific novel modified capsid from specific specific IP licensed from University of Pennsylvania UPenn Jean Bennett/Albert Maguire inventors); AVEXIS / NOVARTIS: 200+; specific SMA innovations (specific specific Zolgensma onasemnogene abeparvovec: specific specific AAV9 capsid from specific specific SMN1 cDNA 2.9 kb from specific specific CB promoter SV40 poly(A) from specific specific 1.1×10^14 vg/kg IV from specific specific infants <2 years at specific specific $2.1M dose FDA 2019 from specific specific AAV9 CNS tropism from specific specific SMA type 1 natural history 20 months fatal vs. specific specific Zolgensma 91% walk 18M from specific specific intrathecal CSF alternative for specific specific larger patients); BIOMARIN: 200+; specific hemophilia innovations (specific specific valoctocogene roxaparvovec ROCTAVIAN: specific specific AAV5 capsid liver tropism from specific specific F.VIII B-domain deleted cDNA 4.9 kb from specific specific HLP hybrid liver-specific promoter ApoE+hAAT from specific specific 4×10^13 vg/kg IV single dose from specific specific FDA August 2023 from specific specific Hemophilia A severe F.VIII <1% from specific specific 50-60% FVIII activity at 52 weeks); BLUEBIRD BIO: 500+; SAREPTA: 500+; ALNYLAM: 2,000+.

Engineered AAV capsid innovations with enhanced tissue specificity, reduced immunogenicity, and improved manufacturability; synthetic promoter innovations for tissue-restricted long-term expression; and AAV manufacturing and purification process innovations represent three core AAV gene therapy patent domains: AAV CAPSID PATENTS: UNIVERSITY OF PENNSYLVANIA; HARVARD; SALK; LACERTA; CAPSIDA: specific capsid innovations (specific specific directed evolution capsid: specific specific AAV shuffling AAV1/2/3/5/6/8/9 VP1/VP2/VP3 genes from specific specific error-prone PCR mutations from specific specific selection on target tissue from specific specific AAVrh10 rhesus macaque CNS retrograde from specific specific AAV-PHP.B Deverman 2016 DGSMSM loop 4 insertion 40× mouse brain vs. AAV9 from specific specific TRAVERSE PHP NHP validation >90% cortex from specific specific anc80L65 ancestral reconstruction: specific specific broad liver eye cochlear tropism from specific specific 60-80% humans naive NAb seroprevalence vs. specific specific AAV2 50-70% AAV9 40-50% from specific specific low neutralizing antibody cross-reactivity from specific specific BI103 AAV10 novel liver low pre-existing immunity); SYNTHETIC PROMOTER PATENTS: SALK; U PENN; MGH; SPARK: specific promoter innovations (specific specific liver-specific HLP hybrid: specific specific ApoE enhancer+hAAT promoter from specific specific 10× vs. CMV/CBA in liver at 52 weeks from specific specific TTR transthyretin 300 bp liver-only from specific specific SYN1 synapsin 600 bp neuron-specific from specific specific VMD2 vitronectin RPE-specific from specific specific compact promoter 1.7 kb vs. CBA 3.7 kb from specific specific enabling larger transgene cargo in AAV from specific specific cPPT+WPRE 3-10× mRNA expression improvement from specific specific BGH bovine growth hormone polyA signal); AAV MANUFACTURING PATENTS: SPARK; AVEXIS; FUJIFILM; THERMO FISHER: specific manufacturing innovations (specific specific triple transfection HEK293: specific specific pAAV-transfer+pHelper+pRepCap plasmids from specific specific CaCl₂ PEI transfection at 300-500L bioreactor from specific specific yield 1×10^15 vg/L optimized from specific specific baculovirus Sf9 insect cell: specific specific rBV-RC rep+cap + rBV-GOI baculovirus from specific specific 200L suspension 1×10^16 vg/L from specific specific 10× HEK293 yield from specific specific iodixanol 40% density gradient: specific specific 100× faster than CsCl₂ from specific specific >90% full capsid purity from specific specific empty:full <5:1 specification from specific specific AVB Sepharose affinity chromatography from specific specific SEC size exclusion 3-step downstream).

Ex vivo lentiviral hematopoietic stem cell HSC gene correction innovations for thalassemia and SCD; Sleeping Beauty and PiggyBac transposon gene insertion innovations for T-cell engineering; and mRNA and circular RNA-based gene therapy innovations represent three additional gene therapy patent domains: LENTIVIRAL EX VIVO PATENTS: BLUEBIRD BIO; AUTOLUS; ORCHARD; GENETHON: specific lentiviral innovations (specific specific self-inactivating SIN lentiviral vector: specific specific deletion U3 LTR ΔU3 3' from specific specific 10^8-10^9 TU/mL titer from specific specific pseudotype VSV-G 4.2 kb cargo limit from specific specific CD34+ HSC transduction 70-80% VCN vector copy number per cell from specific specific LV MOI 5-20 TU/mL from specific specific betibeglogene autotemcel Zynteglo: specific specific βA-T87Q-globin SIN LV from specific specific β-thalassemia transfusion-dependent TDT from specific specific FDA August 2022 from specific specific VCN 0.5-3.0 per HSC from specific specific HbAT87Q >4 g/dL from specific specific LentiGlobin BB305 SCD anti-sickling from specific specific ARSA metachromatc leukodystrophy Libmeldy OTL-200 HSC LV EMA 2020); TRANSPOSON PATENTS: ZIOPHARM; POSEIDA; MOLOGIC; TRANSPOSAGEN: specific transposon innovations (specific specific Sleeping Beauty SB100X: specific specific 100× enhanced transposase vs. original from specific specific >10^5 copies per cell from specific specific random integration non-viral TTAA-specific from specific specific 8 kb cargo vs. LV 8-10 kb from specific specific no LTR insertion vs. LV integration risk from specific specific PiggyBac PB7 hyperactive: specific specific 200 kb cargo capacity from specific specific precise excision from specific specific 17× WT hyperactive from specific specific CAR-T manufacturing non-viral cost reduction: specific specific anti-CD19 CAR 7 kb SB100X electroporation from specific specific 2-log LV cost reduction for specific specific cell therapy startups); RNA GENE THERAPY PATENTS: MODERN; ARCTURUS; TRANSLATE BIO; PRECISION BIOSCIENCES: specific RNA innovations (specific specific circular RNA ciRNA: specific specific IRES internal ribosome entry site from specific specific 3-200 day protein expression half-life vs. linear mRNA 12-24h from specific specific no innate immune TLR7/8 activation from specific specific in vivo mRNA base editing: specific specific ABE mRNA+sgRNA LNP hepatic delivery from specific specific 87% TTR transthyretin reduction Phase 1 NTLA-2001 from specific specific in vivo prime editing: specific specific pegRNA+PE mRNA LNP SCD HbS correction from specific specific 40% HDR vs. 0% mRNA alone from specific specific small-molecule regulated RNA switch iTEP).

Gene therapy startup IP strategy must navigate the dense AAV IP landscape dominated by foundational UPenn IP licensed through Spark/Roche; understand that Novartis AveXis and BioMarin have built strong barriers around AAV9 systemic and AAV5 liver delivery; identify whitespace in novel engineered capsids, novel disease indications, and manufacturing innovations; and develop a regulatory moat through FDA Breakthrough Therapy and RMAT designations: GENE THERAPY STARTUP IP STRATEGY: UNDERSTAND THE GENE THERAPY PATENT LANDSCAPE: UPENN AAV IP IS FOUNDATIONAL — UNDERSTAND ITS SCOPE BEFORE DESIGNING ANY AAV VECTOR: The University of Pennsylvania Jim Wilson lab holds broad foundational AAV capsid IP licensed through Spark/Roche, AveXis/Novartis, and others — most clinical-stage AAV programs carry a UPenn license; startups must determine whether the UPenn license covers their capsid serotype and disease indication; novel engineered capsids (directed evolution, rational design, ancestral reconstruction) falling outside UPenn coverage represent the primary AAV IP whitespace; TROPISM AND IMMUNOGENICITY ARE THE KEY DIFFERENTIATION AXES: Any novel capsid must demonstrate a new tropism profile (new tissue access, CNS penetration, low NAb seroprevalence) vs. existing serotypes — PHP.B (40× CNS mouse) and anc80L65 (60-80% naive NAb, broad liver/eye/cochlear) exemplify what measured performance data creates valuable capsid IP; MANUFACTURING SCALABILITY IS HIGH-VALUE IP: AAV drugs costing $1-3M/dose make manufacturing cost the #1 commercial barrier — triple transfection HEK293 at 500L, baculovirus Sf9 at 200L, novel producer cell lines, and downstream purification process innovations (affinity chromatography, iodixanol gradient, SEC) are highly patentable and commercially critical; WHEN TO PATENT IN GENE THERAPY: NOVEL ENGINEERED AAV CAPSID WITH MEASURED TROPISM AND NAB SEROPREVALENCE: specific novel AAV capsid (design approach + starting sequence) with specific measured biodistribution (vg/cell at target tissue vs. off-target liver lung heart kidney at dose vg/kg in mouse/NHP model; transduction efficiency % transgene-positive cells by flow/IHC; NAb seroprevalence % in human donor serum N≥30 vs. AAV2 50-70% AAV9 40-50% baseline; IC50 NAb titer to neutralize 50% in vitro) vs. best-in-class published capsid (AAV9 CNS, AAVrh10 CNS, anc80L65 liver-eye) — biodistribution + NAb seroprevalence vs. best-published capsid is the most important AAV IP data package; NOVEL MANUFACTURING WITH MEASURED TITER AND PURITY: specific novel process (cell system + production method + purification train) with specific measured performance (titer vg/L at harvest; full:empty capsid ratio; endotoxin EU/mL; residual HEK DNA ppm; residual baculovirus protein ppm; scalability to 200L/2,000L; cost $/vg) vs. HEK293 1×10^15 vg/L or Sf9 baculovirus 1×10^16 vg/L baseline — titer + full:empty ratio + downstream purity vs. published baseline is the key manufacturing IP metric; KEY FTO CHECKLIST: UPenn foundational AAV capsid IP Spark/Roche/Novartis/AveXis licensed; Luxturna AAV2 RPE65 1.5×10^11 vg/eye subretinal FDA 2017; Zolgensma AAV9 SMN1 1.1×10^14 vg/kg SMA IV FDA 2019; ROCTAVIAN AAV5 F.VIII HLP 4×10^13 vg/kg FDA 2023; PHP.B loop 4 DGSMSM 40× CNS; anc80L65 ancestral 60-80% naive NAb; iodixanol 40% 100× CsCl₂ >90% full; AVB Sepharose; Sf9 1×10^16 vg/L 10× HEK; Zynteglo βA-T87Q SIN LV VCN 0.5-3.0 FDA 2022; SB100X 8 kb non-viral; PiggyBac 200 kb; ciRNA IRES 3-200 day no TLR7/8; ABE mRNA LNP 87% TTR Phase 1.